Reserve Bank of India (RBI) has notified that Foreign Institutional Investors (FIIs)/ Foreign Portfolio Investors (FPIs) can now invest from 30% to 40% of the paid up capital of Shilpa Medicare under the Portfolio Investment Scheme (PIS). The company has passed resolutions at its Board of Directors' level and a special resolution by general body agreeing for enhancing the FII/FPI investment limit under Portfolio Investment Scheme up to 40% of the paid up capital of the company.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
